Skip to main content
NIH funding notice RFA-CA-24-010

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Closed on October 1, 2024.

Posted
November 28, 2023
Close date
October 1, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $231,413 in first-year total cost, median $231,413.

Most frequent study sections

  1. Special Emphasis Panel[ZCA1 TCRB-D (O1)]1

Most frequent institutions

  1. MASSACHUSETTS GENERAL HOSPITAL1
Competing awards under RFA-CA-24-010 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2025Streamlining sample preparation with high throughput SpinEx (Separation processing integration for Extracellular vesicles)1R61CA297878-01LEE, HAKHOMASSACHUSETTS GENERAL HOSPITAL, MA$231,413ZCA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-12-0.1.3. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-CA-24-010: Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | ScienceDex | ConductScience